FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164092009> ?p ?o ?g. }

• W3164092009 endingPage "455" @default.
• W3164092009 startingPage "455.1" @default.
• W3164092009 abstract "Background: A definition of difficult-to-treat rheumatoid arthritis (D2T RA) was recently proposed by the European League Against Rheumatism (EULAR) [1]. However, information on the incidence rates of D2T RA in real-world clinical practice is lacking. Objectives: The aim of this retrospective cross-sectional study was to evaluate the incidence rates of D2T RA in clinical practice in Japan. Methods: Data from the Toyohashi RA database (TRAD) was used. The TRAD is a collection of single-center retrospective data. Patients with RA who fulfilled the following three requirements were included in this study: (1) had been treated with >1 biological or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD); (2) >1 year had passed since b/tsDMARD treatment was initiated; and (3) regularly visited our institute at the time of investigation. The number of targeted patients was 363. The criteria of D2T RA used in this study were modified from the EULAR definition for simplification of the investigation as follows: (a) ≥2 b/t DMARDs with different mechanisms of action had been administered; (b) at least moderate disease activity (DAS28-ESR > 3.2 or clinical disease activity index [CDAI] > 10) at the time of investigation; and (c) 7.5-mg/day of prednisolone (PSL) or more was administered at the time of investigation. In this study, D2T RA was defined as criteria (a) + (b) or (a) + (c) or (a) + (b) + (c). The 363 patients were categorized into four groups as follows: group A, DT2 RA; group B, patients with RA who had been treated with ≥2 b/tsDMARDs and did not fulfill the D2T RA definition; group C, RA patients who had been treated with one kind of b/tsDMARD with the same mechanism of action (e.g., two kinds of tumor necrosis factor inhibitors) and fulfilled either or both criteria (b) and (c); and group D, patients with RA who had been treated with one kind of b/tsDMARD with the same mechanism of action (e.g., a tumor necrosis factor inhibitors or two interleukin 6 inhibitors) and did not fulfill either or both criteria (b) and (c). The incidence rates of D2T RA were calculated, and the patients’ characteristics at the time of initiation of the b/tsDMARD treatment were compared between the groups. Results: The number of patients in groups A, B, C, and D were 34, 53, 94, and 182, respectively. Of all the patients included in this study, 9.4% were categorized into group A, those with D2T RA, and 39.1% were treated with ≥2 b/tsDMARDs and categorized into group A (Fig 1). The patients’ characteristics were as follows (group A/B/C/D): mean age (57.1/54.3/61.4/56.2 years), RA duration (10.0/6.7/13.8/8.2 years), %Steinbrocker stage III+IV (%; 84.0/60.0/77.3/54.3), %Steinbrocker class 3 + 4 (%; 68.0/33.3/43.4/23.0), methotrexate (MTX) concomitant rate (%; 79.4/92.5/74.5/91.8), PSL concomitant rate (%; 91.2/52.8/55.3/43.4), DAS28-ESR score (5.5/5.0/5.5/4.7), and CDAI score (12.3/13.7/22.7/16.9). There were statistically significant differences in RA duration, %stage III+IV, %class 3 + 4 and PSL concomitant rate between group A and B. Conclusion: D2T RA occurred in 9.4% of patients treated with b/tsDMARDs. Incidence rate was increased to 39.1% after the treatment with ≥2 b/tsDMARDs. The patients with D2T RA tended to be older, have a long RA duration, be treated without concomitant MTX, be treated with concomitant PSL, and have higher disease activity at the time of starting the b/tsDMARD treatment. The baseline patient characteristics in group C were similar to those in group A. In the future, we suggest that patients with D2T RA be included in group C. References: [1]Nagy et al. Ann Rheum Dis 2021; 80: 31-35. Disclosure of Interests: None declared" @default.
• W3164092009 created "2021-06-07" @default.
• W3164092009 creator A5017609785 @default.
• W3164092009 creator A5018914378 @default.
• W3164092009 creator A5076070750 @default.
• W3164092009 creator A5082533336 @default.
• W3164092009 creator A5087271969 @default.
• W3164092009 date "2021-05-19" @default.
• W3164092009 modified "2023-09-25" @default.
• W3164092009 title "POS0450 INCIDENCE RATES OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS IN REAL-WORLD CLINICAL PRACTICE" @default.
• W3164092009 doi "https://doi.org/10.1136/annrheumdis-2021-eular.1221" @default.
• W3164092009 hasPublicationYear "2021" @default.
• W3164092009 type Work @default.
• W3164092009 sameAs 3164092009 @default.
• W3164092009 citedByCount "1" @default.
• W3164092009 countsByYear W31640920092022 @default.
• W3164092009 crossrefType "journal-article" @default.
• W3164092009 hasAuthorship W3164092009A5017609785 @default.
• W3164092009 hasAuthorship W3164092009A5018914378 @default.
• W3164092009 hasAuthorship W3164092009A5076070750 @default.
• W3164092009 hasAuthorship W3164092009A5082533336 @default.
• W3164092009 hasAuthorship W3164092009A5087271969 @default.
• W3164092009 hasBestOaLocation W31640920091 @default.
• W3164092009 hasConcept C120665830 @default.
• W3164092009 hasConcept C121332964 @default.
• W3164092009 hasConcept C126322002 @default.
• W3164092009 hasConcept C167135981 @default.
• W3164092009 hasConcept C1862650 @default.
• W3164092009 hasConcept C198451711 @default.
• W3164092009 hasConcept C2776715498 @default.
• W3164092009 hasConcept C2777489490 @default.
• W3164092009 hasConcept C2777575956 @default.
• W3164092009 hasConcept C2779974597 @default.
• W3164092009 hasConcept C61511704 @default.
• W3164092009 hasConcept C71924100 @default.
• W3164092009 hasConceptScore W3164092009C120665830 @default.
• W3164092009 hasConceptScore W3164092009C121332964 @default.
• W3164092009 hasConceptScore W3164092009C126322002 @default.
• W3164092009 hasConceptScore W3164092009C167135981 @default.
• W3164092009 hasConceptScore W3164092009C1862650 @default.
• W3164092009 hasConceptScore W3164092009C198451711 @default.
• W3164092009 hasConceptScore W3164092009C2776715498 @default.
• W3164092009 hasConceptScore W3164092009C2777489490 @default.
• W3164092009 hasConceptScore W3164092009C2777575956 @default.
• W3164092009 hasConceptScore W3164092009C2779974597 @default.
• W3164092009 hasConceptScore W3164092009C61511704 @default.
• W3164092009 hasConceptScore W3164092009C71924100 @default.
• W3164092009 hasIssue "Suppl 1" @default.
• W3164092009 hasLocation W31640920091 @default.
• W3164092009 hasOpenAccess W3164092009 @default.
• W3164092009 hasPrimaryLocation W31640920091 @default.
• W3164092009 hasRelatedWork W1964423707 @default.
• W3164092009 hasRelatedWork W1998972628 @default.
• W3164092009 hasRelatedWork W2029476056 @default.
• W3164092009 hasRelatedWork W2045450362 @default.
• W3164092009 hasRelatedWork W2084941600 @default.
• W3164092009 hasRelatedWork W2093618903 @default.
• W3164092009 hasRelatedWork W2130723416 @default.
• W3164092009 hasRelatedWork W2409856569 @default.
• W3164092009 hasRelatedWork W2998679168 @default.
• W3164092009 hasRelatedWork W4247434906 @default.
• W3164092009 hasVolume "80" @default.
• W3164092009 isParatext "false" @default.
• W3164092009 isRetracted "false" @default.
• W3164092009 magId "3164092009" @default.
• W3164092009 workType "article" @default.